Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Texaphyrins: a new approach to drug development
Autore:
Mody, TD; Sessler, JL;
Indirizzi:
Pharmacycl Inc, Sunnyvale, CA 94085 USA Pharmacycl Inc Sunnyvale CA USA 94085 macycl Inc, Sunnyvale, CA 94085 USA Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA Univ Texas Austin TX USA 78712 Dept Chem & Biochem, Austin, TX 78712 USA
Titolo Testata:
JOURNAL OF PORPHYRINS AND PHTHALOCYANINES
fascicolo: 2, volume: 5, anno: 2001,
pagine: 134 - 142
SICI:
1088-4246(200102)5:2<134:TANATD>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
SELECTIVE RADIATION SENSITIZER; PHOTODYNAMIC THERAPY; LUTETIUM-TEXAPHYRIN; CHOROIDAL NEOVASCULARIZATION; GADOLINIUM(III) TEXAPHYRIN; ATHEROMATOUS PLAQUES; LANTHANIDE(III) TEXAPHYRINS; EXPANDED PORPHYRIN; BRAIN METASTASES; REDOX PROPERTIES;
Keywords:
texaphyrin; porphyrin; expanded porphyrin; motexafin gadolinium; motexafin lutetium; photodynamic therapy; photoangioplasty; photosensitizer; radiation sensitization; breast cancer; age-related macular degeneration;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Citazioni:
83
Recensione:
Indirizzi per estratti:
Indirizzo: Mody, TD Pharmacycl Inc, 995 E Arques Ave, Sunnyvale, CA 94085 USA Pharmacycl Inc 995 E Arques Ave Sunnyvale CA USA 94085 94085 USA
Citazione:
T.D. Mody e J.L. Sessler, "Texaphyrins: a new approach to drug development", J PORPHYR P, 5(2), 2001, pp. 134-142

Abstract

The texaphyrins are prototypical metal-coordinating expanded porphyrins. They represent a burgeoning class of pharmacological agents that show promise for an array of medical applications. Currently, two different water-soluble lanthanide texaphyrins, namely motexafin gadolinium (Gd-Tex, 1) and motexafin lutetium (Lu-Tex, 2), are involved in multi-center clinical trials for a variety of indications. The first of these agents, XCYTRIN(R) (motexafin gadolinium) Injection, is being evaluated as a potential X-ray radiationenhancer in a randomized Phase III clinical trial in patients with brain metastases. The second, in various formulations, is being evaluated as a photosensitizer for use in: (i) the photodynamic treatment of recurrent breastcancer (LUTRIN(R) Injection; now in Phase IIb clinical trials); (ii) photoangioplastic reduction of atherosclerosis involving peripheral and coronaryarteries (ANTRIN(R) Injection; now in Phase II and Phase I clinical trials, respectively); and (iii) light-based age-related macular degeneration (OPTRIN(R) Injection; currently under Phase II clinical evaluation), a vision-threatening disease of the retina. In this article, these developments, along with fundamental aspects of the underlying chemistry are reviewed. Copyright (C) 2001 John Wiley & Sons, Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 21:32:22